Registration No. 333-292284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on February 24, 2026. MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification N ...

Earnings Q3 FY26 | February 17, 2025 Contact: investor.relations@medtronic.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade polic ...

Core Viewpoint - Medtronic (MDT) is expected to report its third-quarter fiscal 2026 results on February 17, with earnings per share (EPS) anticipated at $1.33, reflecting a 4.3% decrease year-over-year, while revenues are projected to reach $8.90 billion, indicating a 7.3% growth from the previous year [1][2]. Group 1: Q3 Estimates and Performance - The Zacks Consensus Estimate for Medtronic's third-quarter revenues is $8.90 billion, suggesting a 7.3% increase from the same quarter last year [2]. - The earnings estimate for the third quarter has been revised down by 1 cent to $1.33 per share over the past 60 days [3]. - Medtronic has consistently beaten earnings estimates in the last four quarters, with an average beat of 2.75% [1]. Group 2: Segment Performance Expectations - The Cardiovascular segment is projected to grow by 10.8% year-over-year, driven by the Cardiac Ablation Solutions business and strong performance from the Affera mapping system and Sphere-9 catheter [6][4]. - The Neuroscience segment is expected to see a revenue increase of 5.2% year-over-year, supported by the spine AiBLE ecosystem and growth in Core Spine and Neurosurgery [9][7]. - The Diabetes unit is anticipated to deliver an 11.5% revenue growth, bolstered by new product launches and pent-up demand [15][12]. Group 3: Challenges and Innovations - The Medical Surgical segment has faced challenges due to market pressures from bariatric surgery and a shift towards robotic surgery, but the FDA clearance for the Hugo robotic-assisted surgery system is a positive development [10]. - The Endoscopy business is expected to perform well, driven by growth in esophageal products and the AI-powered GI Genius solution [11]. - Medtronic's Diabetes business is in a strong innovation cycle, with the MiniMed 780G system receiving multiple approvals and a broad U.S. commercial launch [13]. Group 4: Strategic Developments - Medtronic has filed a registration statement for a proposed initial public offering (IPO) as part of a planned separation, allowing the company to focus on high-margin growth markets [14].

As filed with the Securities and Exchange Commission on January 23, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. N ...

As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. Northridge, CA 91325 (763) 514-4000 (Address, including zip ...

Core Insights - Boston Scientific (BSX) is focusing on expanding its global presence to enhance growth opportunities in net sales and market share outside the United States, particularly in Emerging Markets which are expected to account for about 35% of total revenues by 2025 [1][8] Group 1: Global Expansion and Strategy - The company aims to globalize its research and development efforts, moving away from a predominantly U.S.-based model, which is yielding positive results in product development [2] - Boston Scientific has expanded its manufacturing capabilities in China, Costa Rica, and Malaysia, incorporating AI and automation to improve efficiency [2] - In China, the company targets revenues exceeding $1 billion by 2025, leveraging its experienced team and investing in local innovative companies [3] Group 2: Business Segments and Performance - The Interventional Cardiology Therapies (ICTx) segment is noted as the most global business for Boston Scientific, generating nearly 70% of its revenues from international markets [4][8] - Despite slower growth in the U.S., Japan, and Western Europe, the Emerging Markets have supported a double-digit growth rate in the Interventional Cardiology business [4] Group 3: Competitor Updates - Medtronic (MDT) has received FDA approval for its Hugo robotic-assisted surgery system, enhancing its offerings in urologic procedures [5] - Intuitive Surgical (ISRG) has also received FDA clearance for its da Vinci Single Port surgical system for various surgical procedures, expanding its market presence [6] Group 4: Financial Performance and Estimates - Boston Scientific shares have decreased by 3.4% over the past three months, compared to a 5% decline in the industry [7] - The company has a forward one-year Price-to-Earnings (P/E) ratio of 27.50, which is lower than its median but above the industry average [9] - Earnings estimates for Boston Scientific are trending upward, with current estimates for the current year (2025) at $3.04 and next year (2026) at $3.45 [11][12]

Core Insights - Medtronic plc (MDT) has received FDA approval for the Hugo robotic-assisted surgery (RAS) system, enhancing urologic surgical procedures and providing a versatile platform for minimally invasive care [1][9]. Company Developments - The Hugo RAS system builds on Medtronic's existing surgical offerings, including the Touch Surgery ecosystem, to create a connected operating room environment [2]. - Following the announcement on December 3, MDT shares increased by 0.02%, closing at $101.99, indicating a positive market reaction [3]. - Medtronic's current market capitalization stands at $130.73 billion, with an earnings yield of 5.5%, significantly higher than the industry average of 0.1% [4]. Product Features - The Hugo RAS system features a modular design that allows for flexible deployment across various care settings, enhancing utilization and customization for surgeons [5]. - The system includes an open surgeon console that improves situational awareness, reduces physical strain, and offers better training opportunities for surgical teams [5][6]. - It integrates with the Touch Surgery ecosystem, providing pre-operative training, remote tele-proctoring, and AI-driven post-operative insights, making Medtronic the only company to support all surgical modalities [6]. Market Potential - The global urology robotic surgery market is valued at $2 billion in 2024, with a projected CAGR of 8.7% through 2033, driven by the demand for minimally invasive surgeries [10]. - Medtronic plans to expand the Hugo RAS system's applications in the U.S. to include general and gynecologic surgical procedures following its initial urology clearance [7]. Stock Performance - Over the past six months, MDT shares have increased by 16.6%, outperforming the industry, which saw a decline of 1.3% [12].

Core Insights - Medtronic plc (MDT) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.36, a 7.9% increase year-over-year, exceeding the Zacks Consensus Estimate by 3.82% [1] - The company's worldwide revenues for the quarter reached $8.96 billion, reflecting a 6.6% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.11% [2] Revenue Breakdown - MDT's revenues are categorized into four segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes [3] - Cardiovascular revenues grew 9.3% organically to $3.44 billion, with Cardiac Rhythm & Heart Failure sales increasing 14.3% year-over-year to $1.83 billion [4][5] - Medical Surgical sales totaled $2.17 billion, up 1.3% year-over-year, with Surgical & Endoscopy revenues at $1.68 billion, a 1.1% increase [5] - Neuroscience revenues reached $2.56 billion, a 3.9% year-over-year increase, with Neuromodulation revenues growing 7.3% to $520 million [6] - Diabetes segment revenues rose 7.1% organically to $757 million [6] Margin Performance - The gross margin expanded by 90 basis points to 65.8%, despite a 3.9% increase in the cost of products sold [7] - Research and development expenses increased by 8.2% year-over-year to $754 million, while selling, general, and administrative expenses rose 7.5% to $2.97 billion [7] - The adjusted operating margin improved by 50 basis points year-over-year to 24.3% [7] Fiscal 2026 Outlook - Medtronic raised its fiscal 2026 organic revenue growth projection to 5.5% from approximately 5% [10] - The company expects full-year adjusted EPS in the range of $5.62-$5.66, up from the previous range of $5.60-$5.66 [10] - The Zacks Consensus Estimate for fiscal 2026 worldwide revenues is $35.83 billion [10] Strategic Developments - The quarter marked the strongest Cardiovascular revenue growth in over a decade, excluding the pandemic [11] - Medtronic received FDA approval for the Altaviva device and the MiniMed 780G system, enhancing its product offerings [11] - The company anticipates further revenue growth acceleration driven by several enterprise growth drivers, including new therapies and technologies [12]

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as one of the 12 Set-It-and-Forget-It Stocks to buy now, driven by a positive second quarter performance and an executive sale, alongside an expansion opportunity from Medtronic [1] Financial Performance - Abbott reported a 6.9% increase in sales for Q2 2025, with an Adjusted EPS of $1.26, surpassing consensus estimates [2] - The company is progressing in its biosimilars portfolio and expects multiple launches in 2026 [2] Executive Activity - Following the Q2 results, Philip P Boudreau, Executive Vice President and CFO, sold 5,550 shares valued at $746,752 on August 11, 2025, indicating potential negative sentiment [3] Market Opportunities - The FDA cleared Medtronic's MiniMed 780G system on September 2, 2025, which integrates with Abbott's Instinct sensor, providing an opportunity for expansion in diabetes technology [3] Company Overview - Abbott Laboratories has a significant market capitalization of $232.44 billion, establishing a strong presence in the healthcare industry [4] - The company, headquartered in Illinois and operational since 1888, develops and sells a diverse range of medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals globally [4]

Core Insights - Medtronic plc (MDT) has received FDA approval for the Altaviva device, a minimally invasive implantable tibial neuromodulation therapy aimed at treating urge urinary incontinence, marking a significant advancement in bladder control therapies [1][9] - The introduction of the Altaviva device positions MDT as the only company with a comprehensive portfolio of neuromodulation therapies for bladder control symptoms, which is expected to enhance revenue growth and improve stock performance [3][4] Company Developments - The Altaviva device features a 15-year battery life, quick recharging capabilities, and is MRI-compatible, making it a patient-friendly option for those suffering from urge urinary incontinence [6][9] - Medtronic's market capitalization stands at $121.80 billion, with a projected revenue growth of 6.8% for fiscal 2026 compared to fiscal 2025 [4] - The company has consistently outperformed earnings expectations in the past four quarters, with an average surprise of 2.20% [4] Industry Context - Bladder control issues affect approximately 43 million U.S. adults, with nearly 16 million experiencing urge urinary incontinence, indicating a substantial market for the Altaviva device [10] - The global urinary incontinence therapeutics market is expected to grow at a CAGR of 4.0% from 2024 to 2030, driven by an aging population and increased awareness [10]